PPAR-alpha Inhibitors
1 drugsAbout PPAR-alpha
PPAR alpha, or peroxisome proliferator-activated receptor alpha, is a nuclear receptor that regulates lipid metabolism. As a ligand-activated transcription factor, it influences genes involved in fatty acid oxidation and lipoprotein metabolism.
PPAR alpha is a drug target in the metabolic therapeutic area, though no genetic evidence currently links it directly to specific diseases. Drugs like FENOFIBRIC ACID and IQIRVO modulate its activity to address dyslipidemia.
PPAR alpha is targeted by two FDA-approved small molecule drugs: FENOFIBRIC ACID and IQIRVO. These drugs are marketed by Aurobindo Pharma and IPSEN, respectively, for metabolic and other indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Primary Biliary Cirrhosis with only 1 trials.
- phase3 represents biological uncertainty with 0% completion.
Top PPAR-alpha Drugs
Only two companies, Aurobindo Pharma and IPSEN, have approved drugs targeting PPAR alpha.
Low market concentration indicates relatively low barriers to entry for new PPAR alpha-targeting drugs.
PPAR-alpha Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PPAR-alpha, using small molecule modality.
The exclusive use of small molecules suggests an opportunity for novel modalities like antibodies or peptides.
PPAR-alpha Clinical Trials 16 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 | 100% |
| Phase 2 | 4 | 1 | 2 | 1 | 33% |
| Phase 3 | 6 | 0 | 1 | 5 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved PPAR-alpha drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PPAR-alpha. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PPAR-alpha Drug Approval Timeline (2024 - 2024)
The first drug was approved in 2013, and the most recent in 2024, spanning 12 years.
The recent approval suggests renewed interest, but the slow pace indicates potential challenges in development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (8 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 23 clinical trials targeting PPAR-alpha.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities